NEO NeoGenomics, Inc.
NEO NeoGenomics, Inc.
Healthcare · Diagnostics & Research
Market read
POC $10.07 · VWAP $12.48 · +32.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 watchlist
NEO Price Structure
Loading timeframes…
Peers
Every watchlist NEO belongs to, members best 30-day change first — NEO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $0.05 versus analyst consensus of $0.03 (+48.6%).
full note →Against street estimates
How NEO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about NEO from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 17 days ago · Oct 6
- NeoGenomics (NEO) Stock Forecast & Price Prediction 2026–2030 | CoinCodex
- NeoGenomics, Inc. (NEO) Q2 FY2026 earnings call transcript
- NeoGenomics Q3FY26 Results: Revenue ~$209M, Guidance Reiterated
- NeoGenomics Reports Second Quarter 2026 Results
- NeoGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | MarketScreener
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
NEO research tape
58 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.